### Conflict of interest (COI) register

**National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of heart failure in Australia 2018 Working Group**

<table>
<thead>
<tr>
<th>Member</th>
<th>Employment/Current position</th>
<th>Declared interests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Walter Abhayaratna</td>
<td>Clinical Director, Division of Medicine, Director, Clinical Trials Unit, Canberra</td>
<td>Membership with the Medical Advisory Service Committee and European Society of Cardiology Grant received from the NHMRC Sponsored lectures; Amgen, Novartis</td>
</tr>
<tr>
<td>John Atherton</td>
<td>Director of Cardiology Royal Brisbane and Women’s Hospital</td>
<td><strong>Personal, low-level pecuniary interests:</strong> Advisory boards for Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Novartis, Otsuka, Vifor Pharma. Speaker fees from Bristol-Myers Squibb, Menarini, Novartis, Servier. Travel/ accommodation support from Bayer, Boehringer Ingelheim, Novartis, Vifor Pharma. <strong>Non-personal, low-level pecuniary interests:</strong> Research funding from Heart Foundation. Appointed member of the Australian Government Medical Services Advisory Committee. Have not accepted any payment or honoraria for consultancy work or lectures performed after I was asked to chair the heart failure guidelines.</td>
</tr>
<tr>
<td>Ralph Audehm</td>
<td>General practitioner – Carlton and Fitzroy Nth; Honorary Clinical Associate Professor University of Melbourne</td>
<td><strong>Personal, low-level pecuniary interests:</strong> Consultancy, advisory boards: Novartis, Sanofi, Astra Zeneca, Amgen, Mylan Sponsored lectures on diabetes related products and for Amgen regarding their PCSK9 inhibitor. Received monies from National Heart Foundation to deliver lectures/seminars on absolute cardiovascular risk and medication adherence. <strong>Non-personal, low-level pecuniary interest:</strong> Grants received on Heart Failure by the Victorian Department of Health</td>
</tr>
<tr>
<td>Maree Branagan</td>
<td>Senior Clinical Policy Advisor, Heart Foundation</td>
<td>No interests declared</td>
</tr>
<tr>
<td>Member</td>
<td>Employment/Current position</td>
<td>Declared interests</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Tom Briffa       | Exercise Health Professional and Epidemiologist | Non-personal, low-level pecuniary interests:  
NHMRC grant awarded in 2013 on Health Failure MBS/PBS pharmacotherapy, commenced in 2014  
NHMRC CRE awarded 2016 on Cardiovascular Outcome Improvement, commenced in 2016  
Appointed Deputy Chair, National Clinical Issues Committee, National Foundation of Australia, National Office  
Appointed panel member, Future Leader Fellowships, National Heart Foundation of Australia  
Appointed expert member, National Vascular Disease Monitoring Advisory Group, Cardiovascular, Diabetes and Kidney Unit, Canberra |
| Cia Connell      | Manager, Policy and evidence - clinical, Heart Foundation | Personal, non-pecuniary interests:  
Academic: supervisor of research projects in atrial fibrillation  
Academic: author of Therapeutic Guidelines Cardiovascular, Version 7  
Professional: Member of cardiology leadership committee for Society of Hospital Pharmacists of Australia (SHPA) Committee of Special Practice (since 2016)  
Personal, low-level pecuniary interests:  
Money paid to me by SHPA to give presentations about atrial fibrillation (not related to guideline) (2018)  
Money paid by me from Pharmaceutical Society of Australia to write an article for the Australian Pharmacist about aspirin use (June 2017) |
| Carmine De Pasquale | Cardiologist, Flinders Medical Centre | Personal, low-level pecuniary interests:  
Sponsored Advisory Board: Novartis (entresto), Astra Zeneca (dapagliflozin, ZS-9)  
Sponsored Educational Presentation; Novartis, Servier, Vifor, PCM Scientific, Bristol-Myers Squibb, Biotronic, Boehringer Ingelheim, Lily  
Sponsored Heart Failure Educational Programme National Leader (CORE): PCM Scientific (through Novartis unrestricted grant)  
Media (ch 7, 10, ABC radio): Novartis (non-financial)  
Sponsored Pharmaceutical Industry (in house) Educational Lecture: Boehringer Ingelheim Lily |
<table>
<thead>
<tr>
<th>Member</th>
<th>Employment/Current position</th>
<th>Declared interests</th>
</tr>
</thead>
</table>
| Andrea Driscoll | Heart failure Nurse Practitioner, Dept of Cardiology, Austin Health and Professor of Nursing School of Nursing and Midwifery, Deakin University                                                                                       | Personal high-level pecuniary interest: Heart Foundation fellowship  
Personal low-level pecuniary interests: Consultancies and speaker fees: Novartis, Australian Centre for Heart Health  
Nursing Advisory Board: Novartis  
Grants received from Heart Foundation & DHHS  
Personal non-pecuniary interest:  
Academic: supervisor of research projects for Honours, Masters and PhD                                                                                   |
| Ingrid Hopper   | General physician/clinical pharmacologist School of Public Health and Preventive Medicine Monash University                                                                                                               | Personal, non-pecuniary interests:  
Meals provided by Novartis at talks on Entresto, Meal provided by Ferinject                                                                                           |
| Peter Kistler   | Electrophysiologist (EP) Cardiovascular Medicine Services (Heart Centre) The Alfred Hospital                                                                                                                                  | Sponsored Lectures; St Jude/Abbott <$10,000  
Royalties; Up to date, Online Medical Journal <$1,000  
Research grant funding paid to Baker Heart and a Research Institute                                                                                          |
| Peter MacDonald | Medical Director Heart Transplant Unit St Vincent’s Hospital Sydney                                                                                                                                                         | Personal low-level pecuniary interests:  
Advisory boards: Novartis, Astra-Zeneca  
Speaker Fees: Novartis, Servier, Health Pty Ltd  
Novartis Research Grant – paid to St Vincent’s Hospital  
Servier Research Grant – paid to Victor Chang Cardiac Research Institute                                                                                     |
| Phillip Newton  | Nurse/Academic Nursing Research Centre                                                                                                                                                                                            | Non-personal, non-pecuniary interests:  
Chair CSANZ Heart Failure Council  
Memberships; CSANZ, ACNC  
Personal, low-level pecuniary interests:  
Novartis through Cardiology Today for European Society of Cardiology 2017 Summary videos  
Novartis sponsored travel & accommodation to Novartis Heart Failure meeting in 2015, 2016, 2017                                                                 |

Page 3 of 5
<table>
<thead>
<tr>
<th>Member</th>
<th>Employment/Current position</th>
<th>Declared interests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joan O’Loughlin</td>
<td>Consumer representative</td>
<td>No interests declared</td>
</tr>
</tbody>
</table>
| Andrew Sindone | Director, Heart Failure Unit and Department of Cardiac Rehabilitation, Concord Hospital and University of Sydney. | **Personal, low-level pecuniary interests:**  
Advisory boards for pharmaceutical industry; National Cardiac Monitoring Incorporated, Vifor, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharp and Dohme, Novartis, Pfizer, Servier, Otsuka  
Membership; National Cardiac Monitoring Incorporated  
Consultancy; National Cardiac Monitoring Incorporated, Servier  
Expert testimony for Servier  
Sponsored lectures by Mylan Pharmaceuticals, Vifor, Aspen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharp and Dohme, Novartis, Pfizer, Servier and Biotronik  
Sponsored development of presentations by Mylan Pharmaceutical, Vifor, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Pfizer, Servier  
Sponsored travel by Vifor, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Servier  
**Non-personal, low-level pecuniary interest:**  
Grant money provided by Vifor and Biotronik  
**Personal, high level pecuniary interests:**  
Stock held for National Cardiac Monitoring Incorporated |
| Liza Thomas | Cardiologist, Private consultant                                                            | **NHMRC multicentre project grant on chemotherapy related cardiotoxicity**  
Sponsored lectures for Pfizer, Astra Zeneca and Actelion  
Bayer and Servier have sponsored travel to the European Society of Cardiology.  
Structural Heart Disease of Australia sponsored speaker travel expenses  
Philips and Sanofi genzyme sponsored speaker travel expenses  
Sponsored travel for National Heart Foundation Australia selection committee for Future Leader Fellowships  
Investigator initiated grant from Bayer paid to Research and Education Network, Westmead Hospital                                                                 |
<table>
<thead>
<tr>
<th>Member</th>
<th>Employment/Current position</th>
<th>Declared interests</th>
</tr>
</thead>
</table>
| James Wong          | Cardiologist, Director of Echocardiography Laboratory Royal Melbourne Hospital                  | Personal Low level pecuniary interests:  
Sponsored lectures - Boehringer Ingelheim, Bayer, Novatis, Pfizer  
Sponsored accommodation and travel to meetings: Servier Australia, GE Ultrasound, Norvatis  
Bristol Myer Squibb, Bayer  
Personal, non-pecuniary interests:  
MSD Victoria Study – Primary Investigator at Royal Melbourne Hospital  
MSD Victoria Study – Investigators meeting Singapore 2016 at Royal Melbourne Hospital  
Boehringer Ingelheim 12145.121 Study – Primary Investigator 2018 at Royal Melbourne Hospital  
Sanofi – Scored Study – Sub Investigator 2018 at Royal Melbourne Hospital |
| Simon Stewart       | Position declared prior to resignation from working group in October 2017:  
Director, Mary MacKillop Institute for Health Research;  
Director, NHMRC Centre for Research Excellence (CRE) to Reduce Inequality in Heart Disease | Conflicts declared prior to resignation from working group in October 2017:  
Fellowships; supported by an NHMRC Principal Research Fellowship (2012-2017)  
Research Funding; supported by an NHMRC (as Principal Investigator) of a Centre of Research Excellence (2012-2017), Program of Research (2013-2018) and a past NHMRC Project Grant for the WHICH? II Trial of HF management (2012-2016)  
Personal Consultancy; Paid consultancy to Novartis Pharmaceuticals Pty Ltd (Australia) and PCM Scientific, ADEMEDUS Australia Pty Ltd  
Personal Travel Support to Scientific Meetings: Novartis Pharmaceuticals Ltd (Australia)  
Institutional Research Funding: Novartis Pharmaceuticals Ltd (Australia), Pfizer International (Philanthropic Fund) |